AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7867240
Drug: Diltiazem-SR 90
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem-SR 90 mg b.i.d. (increased to 180 mg b.i.d. based on response)
Trial: 2766902
Drug: No enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No enteric-coated aspirin
Trial: 23793
Drug: Camazepam 30
RxNorm normalized name: temazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camazepam 30 mg per day for 20 days
Trial: 30442714
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg administered subcutaneously every 2 weeks
Trial: 29793857
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously every 2 weeks
Trial: 26573454
Drug: Quince syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quince syrup (0.6 cc/kg/day)
Trial: 26573454
Drug: Omeprazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (1 cc/kg/day)
Trial: 21922528
Drug: Palifermin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin (low dose 240μg/kg)
Trial: 21922528
Drug: Palifermin (day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin (day 30 ALC >600 ×106/L)
Trial: 12893983
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg sibutramine daily for 54 weeks
Trial: 16494645
Drug: diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac potassium sachets (50 mg)
Trial: 16494645
Drug: diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac potassium tablets (50 mg)
Trial: 10784227
Drug: Quinapril 10
RxNorm normalized name: quinapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 10 mg daily for 7 days
Trial: 26630717
Drug: Oral-B P35
RxNorm normalized name: Dna plasmid containing genes coding for the human interleukin 12 (il-12) p35 and p40 subunits that are separated by an internal ribosomal entry site (ires) and under the control of a single cytomegalovirus (cmv) promoter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B P35 toothbrush
Trial: 2932989
Drug: Albuterol 200
RxNorm normalized name: ALBUTEROL 200MCG CAP,INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 200 micrograms
Trial: 3485071
Drug: Lactate-gel (pH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-gel (pH 3.5, 5 ml) inserted into the vagina daily for 7 days
Trial: 3485071
Drug: Oral metronidazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronidazole, 500 mg twice daily for 7 days
Trial: 3485071
Drug: Both lactate-gel
RxNorm normalized name: lactate / salicylic acid Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both lactate-gel and metronidazole
Trial: 24675287
Drug: Tamoxifen 30mg
RxNorm normalized name: tamoxifen 30 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 30mg daily for one year
Trial: 22499461
Drug: Home-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based intervention program supervised by home helpers, including a self-administered exercise program and 10 g amino-acid supplementation.
Trial: 12047483
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg single dose on day 1 followed by 62.5 mg twice daily for 5.5 days
Trial: 12047483
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 5.5 days plus ketoconazole 200 mg once daily for 6 days
Trial: 10068176
Drug: OTFC (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTFC (various doses: 200, 400, 600, 800, 1200, 1600 microg)
Trial: 10068176
Drug: Usual rescue
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual rescue drug
Trial: 29566379
Drug: Apabetalone 100mg
RxNorm normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apabetalone 100mg twice-daily for 24 and 26 weeks
Trial: 18628419
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg alone
Trial: 18628419
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + daily medroxyprogesterone acetate (MPA) 2.5 mg
Trial: 18628419
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + cyclical MPA (10 mg days 1‐12 per 28‐day cycle)
Trial: 18628419
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + cyclical micronized progesterone (10 mg days 1‐12)
Trial: 12244891
Drug: 240 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/die Egb 761 (group I = 50 patients)
Trial: 12244891
Drug: 60 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/die Egb 761 (group II = 49 patients)
Trial: 394275
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Diclofenac and Indomethacin)
Trial: 26359580
Drug: Sequential scanning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential scanning technique
Trial: 23115402
Drug: Phentermine 15
RxNorm normalized name: phentermine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15 mg plus extended-release topiramate 92 mg
Trial: 20216464
Drug: L-carnitine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (20 mg kg(‐1) i.v.)
Trial: 17977294
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial agent (control; n = 15)
Trial: 15743361
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg IV bolus, n = 22)
Trial: 15743361
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of somatostatin (500 microg/h, n = 20)
Trial: 11666118
Drug: Total triterpenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA), 60 mg, oral tablets, thrice daily for 12 months
Trial: 9638783
Drug: Adjuvant Psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Psychological Therapy (APT)
Trial: 3290413
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 mg/kg/dose twice daily for 2 weeks)
Trial: 24984785
Drug: ATX-101 1
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 1 mg/cm²
Trial: 24984785
Drug: ATX-101 2
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 2 mg/cm²
Trial: 19080399
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d of prednisone for 7 days
Trial: 19080399
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d of prednisone for 10 days, then tapered to 15 mg/d for 4 days
Trial: 10553827
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg midazolam
Trial: 2008949
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg midazolam
Trial: 6853286
Drug: CVE (central
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVE (central vascular engorgement) via G-suit inflation
Trial: 26817718
Drug: Plasma 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma 25(OH)D concentration ≥ 10 ng/mL compared with <10 ng/mL for women with alcohol intake ≥ 7.1 g/d
Trial: 10358462
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard conservative treatment without octreotide)
Trial: 2663610
Drug: Clonidine (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.9 mg/24 h orally for 72 h)
Trial: 766572
Drug: Lidoflazine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine (60 mg tablet t.i.d.)
Trial: 20530316
Drug: Accelerated-fractionation radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated-fractionation radiotherapy combined with cisplatin therapy
Trial: 20530316
Drug: Standard-fractionation radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-fractionation radiotherapy combined with cisplatin therapy
Trial: 2668407
Drug: Atenolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (mean dose 67 mg/day)
Trial: 2668407
Drug: Diltiazem (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (mean dose 329 mg/day)
Trial: 19672264
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G) 1000 mg m(‐2) on D1, 8, 15 q28d (Arm A)
Trial: 19672264
Drug: Cisplatin (C)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (C) 25 mg m(‐2) followed by Gemcitabine (G) 1000 mg m(‐2) D1, 8 q21d (Arm B)
Trial: 9240593
Drug: Ultralow dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow dose of parenteral estradiol (7.5 microg/24 hours) delivered by vaginal rings
Trial: 8204230
Drug: GA/PM (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA/PM (general anesthesia-parenteral morphine as needed)
Trial: 8204230
Drug: EA/PM (epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA/PM (epidural anesthesia-parenteral morphine as needed)
Trial: 8204230
Drug: EA/EM (epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA/EM (epidural anesthesia-epidural morphine 4 to 5 mg)
Trial: 31749018
Drug: Partial Intervention
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial Intervention (PI), homotaurine administration (100 mg/die) and lessons on the Mediterranean diet
Trial: 28495209
Drug: Moral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moral and conventional rules in daily life
Trial: 26660396
Drug: Basic instructions
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic instructions of oral hygiene (control group)
Trial: 24393153
Drug: Topical regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regular crystalline insulin (containing zinc)
Trial: 24393153
Drug: Aqueous zinc
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous zinc chloride solution
Trial: 22836067
Drug: Niacin therapy
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin therapy
Trial: 19561649
Drug: Oral beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beclomethasone dipropionate (BDP)
Trial: 29401239
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy of underlying conditions (including mineralocorticoid receptor antagonists, statins, ACE inhibitors/ARBs, and cardiac rehabilitation)
Trial: 26670823
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for insomnia, delivered in a five-session format.
Trial: 26670823
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) for insomnia delivered by mental health practitioners.
Trial: 24447519
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (current therapy)
Trial: 23049836
Drug: Monthly installment
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly installment schedule
Trial: 17539894
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg b.i.d. with naltrexone 50 mg
Trial: 17539894
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg b.i.d. and Tegaserod with naltrexone 50 mg
Trial: 9412612
Drug: Piracetam (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (12 g as an initial intravenous bolus, 12 g daily for 4 weeks, and 4.8 g daily for 8 weeks)
Trial: 9412612
Drug: Piracetam (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (in early treatment subgroup)
Trial: 9412612
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in early treatment subgroup)
Trial: 8213795
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa solution
Trial: 25439595
Drug: sham/0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham/0.5 mg crossover
Trial: 12743672
Drug: Ximelagatran 20
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 20 mg twice daily, administered either before breakfast and with dinner, or with breakfast and after dinner.
Trial: 12743672
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of ximelagatran (1-98 mg) in a dose-escalation study.
Trial: 8362451
Drug: Mebendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (400 mg)
Trial: 20462038
Drug: Kangliu Zengxiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangliu Zengxiao Decoction (KLZX) in addition to chemotherapy NP regimen
Trial: 20462038
Drug: Chemotherapy NP
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy NP regimen alone
Trial: 18678792
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion hydrochloride started at 150 mg/d and increased to 400 mg/d
Trial: 18678792
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride started at 50 mg/d and increased to 200 mg/d
Trial: 18678792
Drug: Extended-release venlafaxine
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release venlafaxine hydrochloride started at 37.5 mg/d and increased to 375 mg/d
Trial: 15900007
Drug: Doxorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50 mg/m2) plus docetaxel (75 mg/m2)
Trial: 15900007
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2)
Trial: 8712652
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulphate (MST) and 10 mg metoclopramide every 8 h for 48 h
Trial: 8712652
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac twice daily for 48 h
Trial: 8712652
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulphate (MST)
Trial: 1655107
Drug: Sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbinil (250 mg day‐1) for 4 weeks
Trial: 1655107
Drug: Sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbinil (250 mg day‐1) for 52 weeks
Trial: 7035745
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including platinum
Trial: 29989335
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec U100 (Deg)
Trial: 25030181
Drug: Exenatide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2.5 µg + insulin
Trial: 16183427
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (control)
Trial: 25030181
Drug: Pramlintide 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 30 µg + insulin
Trial: 14741079
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg/day for 6 days
Trial: 7506144
Drug: Nimesulide 200
RxNorm normalized name: nimesulide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 200 mg/day
Trial: 9777717
Drug: Erig PMC
RxNorm normalized name: Erigeron strigosus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erig PMC (40 IU kg(‐1) via intramuscular route)
Trial: 9777717
Drug: PHT‐Erig (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT‐Erig (40 IU kg(‐1) via intramuscular route)
Trial: 9777717
Drug: Erig PMC
RxNorm normalized name: Erigeron strigosus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erig PMC (40 IU kg(‐1) via intramuscular route) with PVRV
Trial: 9777717
Drug: PHT‐Erig (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT‐Erig (40 IU kg(‐1) via intramuscular route) with PVRV
Trial: 2460568
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon gel (10^6 IU of leukocyte interferon/g)
Trial: 2460568
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon gel with nonoxynol-9
Trial: 2460568
Drug: Placebo (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gel base alone)
Trial: 31595423
Drug: CoQ10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (300 mg, once daily) for 12 months in RTT patients
Trial: 31595423
Drug: CoQ10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (300 mg) for 30 days in healthy adults
Trial: 31595423
Drug: EGCG (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (1 g green tea extract containing 50% EGCG) for 30 days in healthy adults
Trial: 31595423
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1 g) for 30 days in healthy adults
Trial: 31595423
Drug: Resveratrol (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (325 mg) for 30 days in healthy adults
Trial: 23688751
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab combined with glucocorticoids (prednisone 60, 30, 20, 10 mg/day on days 5-28)
Trial: 23688751
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab combined with glucocorticoids (prednisone)
Trial: 23688751
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dexamethasone 40 mg/day on days 1-4, followed by rituximab 100 mg on days 7, 14, 21, 28)
Trial: 17315708
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus 10 longidase injections in a dose of 3000 IU
Trial: 12817526
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg alone for 10 days
Trial: 12817526
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg with Crataegus special extract WS 1442 (hawthorn) 450 mg twice daily for 21 days
Trial: 10917408
Drug: Gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600 to 3,600 mg/day)
Trial: 8672615
Drug: Metamizol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol (1 g/100 ml NaCl 0.9%)
Trial: 8672615
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml NaCl 0.9%)
Trial: 6375890
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of tyrosine-adsorbed, glutaraldehyde-modified Dermatophagoides pteronyssinus antigen
Trial: 30100320
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SS and remote MFR
Trial: 30100320
Drug: Self‐administered interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered interventions (all groups)
Trial: 27051992
Drug: Caffeinated drink
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated drink (80 mg of caffeine)
Trial: 25725933
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC 10-mg
Trial: 25725933
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC 20-mg
Trial: 25725933
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC (10-mg and/or 20-mg)
Trial: 23593607
Drug: ETV (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV (1 mg) monotherapy
Trial: 23593607
Drug: LAM+ADV combination
RxNorm normalized name: Viril Lam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM+ADV combination therapy
Trial: 23593607
Drug: ETV (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV (1 mg)+ADV combination therapy